Treatment of moderate to severe atopic dermatitis with dupilumab in real clinical practice. Baseline characteristics of patients from 5 reference dermatology units included in the dupilumab expanded access in Spain

Introduction: Atopic dermatitis (AD) is a chronic, inflammatory and pruritic skin disease, with a prevalence of 1-3% of the adult population. Usually begins in early childhood, progresses with a recurrent course before disappearing at puberty, and may persist to adulthood or present de novo during this period. It is frequently associated with elevated levels of serum IgE, individual or family history of type I allergies, allergic rhinitis and asthma. The therapeutic approach in adult AD patients can be frankly complicated beyond topical treatments, as phototherapy and/or systemic therapies often do not guarantee adequate control of the disease.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research